Durvalumab approved as first immunotherapy for patients with LS-SCLC

Durvalumab has been approved as a monotherapy in Switzerland for the treatment of adult patients with unresectable small cell lung cancer (LS-SCLC, limited-stage small cell lung cancer) whose disease has not progressed after platinum-based chemoradiotherapy (CRT) [1]. It offers a new treatment option that has been shown to improve the survival of patients with this aggressive form of lung cancer.